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ABSTRACT Hepatitis C virus (HCV)-specific CD8 T cells suffer a progressive exhaus-
tion during persistent infection (PI) with HCV. This process could involve the positive
immune checkpoint 4-1BB/4-1BBL through the loss of its signal transducer, TRAF1.
To address this issue, peripheral HCV-specific CD8 T cells (pentamer-positive [pen-
tamer]/CD8 T cells) from patients with PI and resolved infection (RI) after treat-
ment were studied. The duration of HCV infection and the liver fibrosis progression
rate inversely correlated with the likelihood of detection of peripheral pentamer/
CD8 cells. In PI, pentamer/CD8 cells had impaired antigen-specific reactivity that
worsened when these cells were not detectable ex vivo. Short/midduration PI was
characterized by detectable peripheral PD-1 CD127low TRAF1low cells. After trigger-
ing of T cell receptors (TCR), the TRAF1 level positively correlated with the levels of
CD127, Mcl-1, and CD107a expression and proliferation intensity but negatively with
PD-1 expression, linking TRAF1low to exhaustion. In vitro treatment with interleukin-7
(IL-7) upregulated TRAF1 expression, while treatment with transforming growth
factor-1 (TGF-1) did the opposite, suggesting that the IL-7/TGF-1 balance, be-
sides TCR stimulation, could be involved in TRAF1 regulation. In fact, the serum
TGF-1 concentration was higher in patients with PI than in patients with RI, and it
negatively correlated with TRAF1 expression. In line with IL-7 increasing the level of
TRAF1 expression, IL-7 plus 4-1BBL treatment in vitro enhanced T cell reactivity in
patients with short/midduration infection. However, in patients with long-lasting PI,
anti-PD-L1, in addition to the combination of IL-7 and 4-1BBL, was necessary to rees-
tablish T cell proliferation in individuals with slowly progressing liver fibrosis (slow fi-
brosers) but had no effect in rapid fibrosers. In conclusion, a peripheral hyporeactive
TRAF1low HCV-specific CD8 T cell response, restorable by IL-7 plus 4-1BBL treat-
ment, characterizes short/midduration PI. In long-lasting disease, HCV-specific CD8
T cells are rarely detectable ex vivo, but treatment with IL-7, 4-1BBL, and anti-PD-L1
recovers their reactivity in vitro in slow fibrosers.
IMPORTANCE Hepatitis C virus (HCV) infects 71 million people worldwide. Two-
thirds develop a chronic disease that can lead to cirrhosis and hepatocellular carci-
noma. Direct-acting antivirals clear the infection, but there are still patients who re-
lapse. In these cases, additional immunotherapy could play a vital role. A successful
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anti-HCV immune response depends on virus-specific CD8 T cells. During chronic
infection, these cells are functionally impaired, which could be due to the failure of
costimulation. This study describes exhausted specific T cells, characterized by low
levels of expression of the signal transducer TRAF1 of the positive costimulatory
pathway 4-1BB/4-1BBL. IL-7 upregulated TRAF1 expression and improved T cell reac-
tivity in patients with short/midduration disease, while in patients with long-lasting
infection, it was also necessary to block the negative PD-1/PD-L1 checkpoint. When
the results are taken together, this work supports novel ways of restoring the spe-
cific CD8 T cell response, shedding light on the importance of TRAF1 signaling.
This could be a promising target for future immunotherapy.
KEYWORDS 4-1BB, CD8 T cell response, IL-7, PD-1, T cell exhaustion, TGF-1, TRAF1,
hepatitis C virus, immune checkpoint, immunotherapy
Hepatitis C virus (HCV)-specific CD8 T cells are vital for the clearance of HCV (1) andmight play a role in the avoidance of relapses because of the temporary presence
of trace levels of occult virus after the treatment-induced control of HCV infection (2–7).
Nevertheless, during persistent infection (PI) with HCV, this response either is exhausted
or is even deleted (8–11). Several strategies have focused on the modulation of immune
checkpoints to restore in vitro T cell reactivity and have had variable success (8, 12, 13).
The progenitor T cell pool could be a sound candidate as a subset responsive to
immunotherapeutic approaches (14, 15). However, it has been shown that this popu-
lation can develop a gradient of functional impairment according to the infection stage
(16, 17). During PI, the presence of peripheral HCV-specific CD8 T cells at a frequency
below the detection threshold of conventional methods (18) might suggest deletion of
the terminal effector memory population and an intense impairment of the progenitor
subset, while the presence of detectable cells could be linked to less severe exhaustion
(9, 15, 16). Therefore, an immunomodulatory strategy to restore T cell numbers could
yield different results, according to whether the detection of peripheral HCV-specific T
cells ex vivo is possible or not.
The triggering of the immune checkpoint tumor necrosis factor (TNF) receptor
superfamily member 9 (4-1BB)/4-1BB ligand (4-1BBL) (19) to improve the HCV-specific
CD8 T cell response has already been tested, but unfortunately, it was shown to have
weak efficacy (13). This failure could be due to the impairment of signal transduction.
TNF receptor-associated factor 1 (TRAF1) is the key transducer of this pathway (20).
TRAF1 levels are low in resting cells but are upregulated via NF-B after T cell activation
(21, 22). TRAF1 loss is observed during some chronic viral infections, such as those with
murine lymphocytic choriomeningitis virus (LCMV) (23). Of note, besides triggering T
cell receptors (TCR), interleukin-7 (IL-7) upregulates TRAF1 expression during LCMV
infection, while triggering of transforming growth factor-1 (TGF-1) does the opposite
(23). Several mechanisms could be involved in inducing TGF-1 secretion during
chronic HCV infection (24–26), and consequently, the induction of TGF-1 secretion
could affect TRAF1 expression. Thus, IL-7 could potentially be utilized (27) to restore
TRAF1 levels by counteracting the effect of TGF-1 in those exhausted T cells not able
to upregulate TRAF1 after TCR stimulation. The role of IL-7 in TRAF1 expression in
HCV-specific CD8 T cells during PI has not been studied before. Our work shows that
during short/midduration infection, exhausted TRAF1low-expressing HCV-specific CD8 T
cells are generally detectable in the peripheral compartment and are amenable to IL-7
plus 4-1BB triggering. On the contrary, during long-lasting disease, these cells are
commonly present at levels below the direct detection threshold ex vivo and the
additional blockade of the programmed cell death protein 1 (PD-1) checkpoint is
necessary to restore their reactivity. These findings provide novel insight into the role
of TRAF1 in the functional impairment of HCV-specific CD8 T cells, which could open
new opportunities for those patients not responding to direct-acting antivirals (DAA)
(28) as well as patients with other chronic viral infections and cancer.
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Ex vivo pentamer-positive (pentamer)/CD8 cell detection correlates with the
duration of HCV infection and the liver fibrosis progression rate. The groups with
RI and PI displayed comparable demographic and clinical features (Table 1). In both
groups, peripheral blood lymphocytes (PBL) were tested for the presence of CD8 T
cells specific for two human leukocyte antigen (HLA)-A2-restricted HCV genotype 1 NS3
epitopes. Sequencing of the epitope consisting of HCV NS3 from positions 1073 to 1081
(NS31073–1081; also referred to here as the NS31073 epitope) and the epitope consisting
of HCV NS3 from positions 1406 to 1415 (NS31406 –1415; also referred to here as the
NS31406 epitope) could be performed for 66% of the patients with PI. Remarkably, the
sequences of 100% of the NS31073 epitopes and 70% of the NS31406 epitopes tested
were similar to those of the peptides loaded into the pentamers (Table 2). As HCV
isolates from patients with RI were not available for sequencing, due to a lack of
pretreatment serum samples, in order not to bias the analysis, all samples were








Median (IQR) age (yr) 57 (13) 55 (13) NSb
% of male patients 67 63 NSc
Median (IQR) duration of infection (yr) 34 (12) 36 (12) NSb
% of patients with HLA-A2 100 100 NSc
% of patients infected with HCV genotype 1 100 100 NSc
% of patients with the following source of infection:
Unknown 12 6 NSc
IVDA 5 9 NSc
Otherd 83 85 NSc
No. of patients previously treated with:
No treatment 0 20 NA
P-IFN  RBV 11 12 NA
P-IFN  RBV  DAA 12 3 NA
DAA regimen 19 0 NA
Median (IQR) HCV viral load (IU · ml1, log scale) UDL 6.2 (0.79) 0.001b
Median (IQR) ALT concn (IU · ml1) 17 (7) 47 (73) 0.001b
% of patients with the following degree of liver
fibrosise:
F0 to F2 43 57 NSc
F3 or F4 57 43
% of patients with the following fibrosis speed:
Slow (0.06 unit · year1) 31 37 NSc
Mid/rapid (0.06 unit · year1) 69 63
No. of patients with the following NS31073 sequence:
WT ND 24 NA
EV ND 0 NA
Unknown ND 11 NA
No. of patients with the following NS31406 sequence:
WT ND 14 NA
EV ND 6 NA
Unknown ND 12 NA
aALT, alanine aminotransferase; DAA, direct-acting antiviral; EV, escape variant; IQR, interquartile range; IVDA,
intravenous drug abuse; NA, not applicable; NS, nonsignificant; ND, not done; P-IFN, pegylated alpha2
interferon; PI, persistent infection; RBV, ribavirin; RI, resolved infection; UDL, under the detection limit; WT,
wild type.
bDetermined by the Mann-Whitney U test.
cDetermined by the chi-square test.
dParenteral nonintravenous drug abuse or sexual transmission.
eThe degree of liver fibrosis was estimated by transient elastography or liver biopsy.
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included for comparisons of patients with PI and RI and also when TRAF1 was the
independent variable. In other tests carried out in the PI group, those cases with known
HCV escape variants were excluded when TRAF1 was the dependent variable.
The frequency of cases with peripheral HCV-specific pentamer/CD8 cells detect-
able ex vivo was similar between the RI and PI groups (Fig. 1A). In patients with PI,
cytomegalovirus (CMV) pentamer/CD8 cells were more frequently detected than
HCV pentamer/CD8 cells (Fig. 1A), probably due to persistent antigen stimulation in
both pools without exhaustion of the CMV-specific T cell population. Interestingly, the
predictive factors associated with the detection of peripheral HCV pentamer/CD8
cells were both the duration of HCV infection and the degree of liver fibrosis. A negative
correlation between the HCV infection span and the detection of peripheral HCV
pentamer/CD8 cells was observed in both patients with PI and patients with RI (Fig.
1B; Table 2). In particular, among those patients who had been infected for less than 40
years, pentamer-binding CD8 cells were observed in 52% of slow fibrosers (liver
fibrosis progression rate, 0.06 units · year1) and 32% of mid-rapid-fibrosing cases
(liver fibrosis progression rate, 0.06 units · year1). In contrast, among cases with
more than 40 years of disease progression, these cells were detected in only 15% of
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FIG 1 Ex vivo detection of pentamer/CD8 cells. (A) Frequency of patients with resolved and persistent infections and HCV NS31073-, HCV NS31406-, and CMV
pp65495-specific pentamer/CD8 cells detectable ex vivo. (B) Correlation between HCV infection length and detection of peripheral HCV pentamer/CD8 cells
ex vivo, unbundled according to liver fibrosis stage. Box plots represent the distribution of the infection duration in each category when the data for patients
with persistent infection and resolved infection after treatment are taken together. (C) Frequency of cases with peripheral pentamer/CD8 cells detectable
ex vivo in relation to the duration of HCV infection (short/midduration, 40 years; long lasting, 40 years) and the rate of liver fibrosis progression. #, chi-square
test; ¤, Spearman correlation test; ‡, Mann-Whitney U test; §, linear trend test; F, Metavir fibrosis stage; ND, not done; NS, nonsignificant; PI, persistent infection;
RI, resolved infection after treatment; *, comparison between HCV-pentamer/CD8 and CMV-pentamer/CD8 cells in PI.
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Therefore, the duration of infection and the rate of liver fibrosis progression
emerged as key factors determining the presence of detectable peripheral HCV-specific
CD8 T cells by standard pentamer staining.
Impairment of HCV pentamer/CD8 cell reactivity during PI. PBL from patients
with RI and PI were challenged in vitro for 10 days with HCV-specific peptides (NS31406
and NS31073) and in parallel with the CMV pp65 peptide from positions 495 to 504
(pp65495–504; also referred to here as the pp65495 peptide) as an internal control for
patients with PI. In patients with RI, we observed an expansion of 72% of NS31073-
specific pentamer/CD8 cells and 49% of NS31406-specific pentamer/CD8 cells,
while only 39% of NS31073-specific pentamer/CD8 cells and 27% of NS31406-specific
pentamer/CD8 cells from the PI group expanded (Fig. 2A). In cases with detectable
cells ex vivo, 100% of NS31406-specific pentamer/CD8 cells and NS31073-specific
pentamer/CD8 cells from patients with RI proliferated, whereas 77% of NS31073-
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FIG 2 Antigen-specific reactivity of pentamer/CD8 cells. (A) Global frequency of cases with pentamer/CD8 cell expansion after 10 days (d) of specific
stimulation. (B) Intensity of pentamer/CD8 cell proliferation in patients with resolved infection (RI) after treatment and persistent infection (PI), according to
the presence of pentamer/CD8 cells detectable ex vivo. The percentages of cases with positive expansion are indicated. The duration of infection (in years)
is described as the median plus interquartile range (IQR). Box plots summarize the distribution of pentamer/CD8 cell frequency after expansion after pooling
of all samples tested in each category. (C) Representative dot plots showing pentamer/CD8 cells in the upper right quadrant, according to the duration of
infection and the rate of liver fibrosis progression both ex vivo and after 10 days of specific in vitro challenge. The Metavir score is displayed in bold in the upper
left corner. The percentage of pentamer/CD8 cells is in reference to the number of total CD8 cells. d, day; #, chi-square test; ¥, Mann-Whitney U test; ID,
patient identification; LOD, limit of detection.
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from patients with PI proliferated (Fig. 2B and C). Moreover, after pooling of the data
for both epitopes, the intensity of the proliferation, measured as the percentage of
pentamer/CD8 cells out of the total CD8 cells, was higher in patients with RI
(11.4%) than in patients with PI (0.58%) (Fig. 2B and C). In those cases with no
pentamer/CD8 cells detectable ex vivo, the proliferation was globally lower but still
different between the two groups. When the results for the two NS3 epitopes were
combined, 47% of pentamer/CD8 cells proliferated for the RI group but only 22%
proliferated for the PI group (Fig. 2B and C). The proliferation impairment in patients
with PI was HCV specific, since 100% of paired CMV pp65495 pentamer/CD8 cells
from those patients expanded after specific in vitro challenge (Fig. 2B).
These data showed a weakening of the peripheral HCV-specific CD8 cell reactivity
during chronic infection that was deeper in patients with long-lasting infection, which
could suggest the presence of different subsets of target cells according to the duration
of HCV infection.
Different HCV pentamer/CD8 cell differentiation between PI and RI. In 16
selected samples in which cells were detectable ex vivo, we performed an extended
analysis of the memory phenotype to describe better the baseline features of specific
T cells. In the RI group, 85% of HCV pentamer/CD8 cells displayed an effector
memory phenotype (CD45RA, CD28, CCR7). In contrast, the patients with PI
showed a different memory phenotype distribution, defined by minor subsets of
RA-positive (RA) effector memory T cells (TEMRA; CD45RA, CD28, CCR7) and
naive-like cells (CD45RA, CD28, CCR7) and a major pool of CD28-expressing
effector memory cells (Fig. 3). The central memory subset (CD45RA, CD28, CCR7)
was a minor population in both groups, probably because most of the patients with RI
were studied shortly after the sustained viral response. Therefore, a heterogeneous
population of peripheral HCV-specific CD8 T cells but with a significant subset of
CD28 cells, which have previously been considered the source for a positive response
to immune modulation, was detected in patients with PI (29).
TRAF1low expression in pentamer/CD8 cells after triggering of TCR during
PI. A pilot analysis of TRAF1 expression in HCV pentamer-binding CD8 cells performed
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FIG 3 Memory phenotype of pentamer/CD8 cells ex vivo. (A) Frequency of peripheral central memory effector memory, effector memory RA (TEMRA), and
naive-like pentamer/CD8 cells in cases with resolved and persistent infections. Œ, outlier value; *, extreme value. (B) Representative dot plots showing the
memory phenotype of pentamer/CD8 cells. Black dots, pentamer/CD8 cells; gray scale, total CD8 cells. The data represent the percentage of
pentamer/CD8 cells in each quadrant in reference to the number of total pentamer/CD8 cells. ID, patient identification; ¥, Mann-Whitney U test.
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than in patients with PI (Fig. 4). PBL were challenged in vitro for 3 h with specific
peptides in order to increase the levels of protein expression in both groups, since
TRAF1 is an NF-B-inducible protein with low levels of expression in resting cells (21,
22). TRAF1 was upregulated in patients with RI but not in patients with PI after 3 h of
specific triggering of TCR (Fig. 4). According to this strategy and after pooling of the
data for the two HCV epitopes tested, the induction of TRAF1 expression in HCV
pentamer/CD8 cells after 3 h of specific stimulation was higher in patients with RI
(mean fluorescence intensity [MFI], 120; interquartile range [IQR], 70) than in patients
with PI (MFI, 80; IQR, 37) (Fig. 5A, C, and D). HCV pentamer/CD8 cells from patients
with RI and CMV pentamer/CD8 cells from patients with PI displayed similar levels
of TRAF1 induction, both of which were higher than those displayed by HCV penta-
mer/CD8 cells from patients with PI (Fig. 5A and C). The level of TRAF1 expression
by bulk CD8 cells from patients with RI and PI stimulated with HCV and CMV peptides,
respectively, was also higher than that by total CD8 cells from patients with PI
stimulated with HCV peptides, although it was significantly lower than that by their
paired pentamer/CD8 cells (Fig. 5A and C). This fact could be due to CD8 cell
bystander activation during the 3-h PBL-specific stimulation in those cultures with a
nonexhausted specific CD8 T cell response to the cognate antigen (30).
According to the level of Alexa Fluor 647 (AF647) MFI expression in the negative
controls, three different levels of TRAF1 expression were defined in pentamer/CD8
cells. TRAF1low expression was considered a value lower than the median for the
negative control (34 MFI) plus 1.5 the IQR value, which was 45 (TRAF1low MFI, 100).
TRAF1dim expression was defined as a value lower than 3 times the upper limit of
TRAF1low expression (TRAF1dim MFI, 100 to 300). TRAF1high expression was defined as






















































































Directly ex-vivo After 3h specific st
Gated on bulk CD8+ cells
AF647
Negative control
MFI 130 MFI 231
MFI 42 MFI 46
MFI 48 MFI 41
MFI 35 MFI 33
Negative control TRAF1
FIG 4 Pilot analysis of TRAF1 expression in pentamer/CD8 cells from patients with resolved and persistent infections performed directly ex vivo and after
3 h of specific stimulation. Box plots (A) and representative dot plots (B) from a preliminary analysis show the level of TRAF1 expression in HCV
pentamer-binding CD8 cells determined directly ex vivo and after 3 h of specific stimulation in patients with a resolved infection after treatment and patients
with persistent infection. Negative control, T cell labeling with the secondary antibody only; MFI, mean fluorescence intensity; NS, nonsignificant; st, stimulation;
§, Mann-Whitney U test; ¥, Wilcoxon test.
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Using these values as cutoffs, in the RI group, 70% of tested samples showed TRAF1dim
expression after 3 h of specific stimulation, while only 20% of samples from the PI group
showed TRAF1dim expression (Fig. 5A) (P  0.003). Moreover, in 11 out of 15 patients
with PI in whom TRAF1 expression was analyzed, sequencing of the HCV epitope was
performed. The difference in the level of TRAF1 induction between pentamer-binding
and total CD8 cells after antigen-specific triggering was lower in samples from wild-type
HCV-infected cases than in the two samples harboring escape variants with the already
described impaired cross-recognition by wild-type HCV-primed T cells (NS31406, L1410M)
(32) (Fig. 5E).
In 26 patients with RI and 9 patients with PI with a preserved pentamer/CD8 cell
expansion ability, TRAF1 expression was tested after a 10-day specific in vitro challenge.
The level of TRAF1 expression was higher than that obtained directly ex vivo and higher
than that by paired total CD8 cells (Fig. 5B and C). In fact, in 85% of the experiments
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FIG 5 TRAF1 expression in pentamer/CD8 cells. (A and B) MFI of TRAF1 in peripheral total CD8 and pentamer/CD8 cells after 3 h (A) and after 10 days
(B) of specific in vitro challenge, depending on the viral control. According to the MFI, TRAF1 expression was categorized as negative (Neg), dim, and high. The
box plots summarize the distribution of the TRAF1 MFI in total and pentamer-binding CD8 cells in each category. (C) Representative dot plots showing TRAF1
expression in pentamer/CD8 cells after 3 h and 10 days of specific in vitro challenge in patients with resolved and persistent infections. The data represent
the percentage of cells in each area in reference to the number of total CD8 and pentamer/CD8 cells. (D) Histograms of TRAF1 expression by pooled HCV
and CMV specific pentamer/CD8 cells from all patients with resolved infection after treatment and persistent infection after 3 h of specific stimulation. (E)
Difference in TRAF1 expression according to the MFI between NS3 pentamer/CD8 and total CD8 cells from patients with PI infected by wild-type HCV NS3
or an escape variant. Bold lines, median values of the distribution; #, Mann-Whitney U test; ¤, Wilcoxon test. Œ, outlier value; *, extreme value; Ag, antigen; MFI,
mean fluorescence intensity; ND, not done; Negative Control, T cell labeling with the secondary antibody only; NS, nonsignificant; Pent, pentamer.
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In patients with RI, the induction of TRAF1 expression was comparable in patients
treated with interferon (IFN)-free and IFN-containing regimens (Fig. 6). Two patients
with PI could be longitudinally studied during anti-HCV treatment with DAA for 12
weeks. In these cases, TRAF1 expression was upregulated in pentamer/CD8 cells at
the end of treatment and 12 weeks after the cessation of treatment, and this correlated
with an improvement in both the frequency of peripheral pentamer-binding CD8 cells
ex vivo and the proliferation intensity of pentamer-binding CD8 cells. After treatment,
these cells acquired a PD-1dim CD127dim phenotype, suggesting that they could belong
to the T cell factor 1 (TCF1)-positive (TCF1) PD-1 CD127 progenitor pool recently
described (17) (Fig. 7).
Thus, persistent HCV infection could induce the low level of expression of TRAF1 in
peripheral HCV-specific CD8 T cells; however, in cases in which these cells are not
severely exhausted and still maintain their proliferative potential, they are able to
acquire a TRAF1high phenotype.
Correlation between TRAF1low expression and exhaustion phenotype. When all
cases with HCV pentamer-binding CD8 cells directly detectable ex vivo were taken
together, induction of TRAF1 expression in pentamer/CD8 cells after 3 h of specific
stimulation positively correlated with CD127 and Mcl-1 expression but negatively
correlated with PD-1 expression (Fig. 8A and D). After 3 h of specific triggering of TCR,
TRAF1dim pentamer/CD8 cells showed higher levels of CD127 and Mcl-1 expression
but lower levels of PD-1 expression than TRAF1low-expressing cells (Fig. 8B and E).
TRAF1dim cells also had a higher intensity of proliferation than TRAF1low pentamer/
CD8 cells (Fig. 8C and D). Moreover, the percentage of CD107a-positive cells detect-
able ex vivo was higher in the TRAF1dim cell population (41%) than in the TRAF1low cell
population (3%) (Fig. 9). In contrast, the level of gamma interferon (IFN-) secretion ex
vivo was similarly low between the TRAF1dim and TRAF1low groups. However, after
specific in vitro expansion, IFN- and CD107a were upregulated in cells of both groups
with a preserved expansion ability (Fig. 9). The clinical features of the patients with the









































































MFI: 231 MFI: 152
MFI: 143 MFI: 163
FIG 6 TRAF1 expression in pentamer/CD8 cells from resolved infection cases after interferon-free and interferon-containing regimens. Box plots (A) and
representative dot plots (B) showing the level of TRAF1 expression after 3 h of antigen-specific stimulation in HCV pentamer-binding CD8 cells from
sustained virologic responders to interferon (IFN)-containing and -free regimens. MFI, mean fluorescence intensity; NS, nonsignificant; §, Mann-Whitney U
test.
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Hence, after specific triggering of the TCR the existence of the TRAF1low phenotype
could point to T cell exhaustion and TRAF1 upregulation could be considered a
potential tool to enhance T cell reactivity.
IL-7 upregulates TRAF1 expression, while TGF-1 does the opposite. After
describing a significant positive correlation between IL-7 receptor and TRAF1 expres-
sion, we analyzed whether treatment with IL-7 in vitro could upregulate TRAF1 expres-
sion in pentamer/CD8 cells. In 8 out of 9 samples, TRAF1 expression in pentamer/
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272P
FIG 7 TRAF1 kinetics in pentamer/CD8 cells during treatment with direct-acting antivirals. Longitudinal dot plots show the peripheral ex vivo frequency, the
proliferation intensity after specific in vitro challenge, the PD-1/CD127 level obtained directly ex vivo, and the level of TRAF1 expression after 3 h of specific
stimulation in pentamer/CD8 cells from two HCV genotype 1-infected patients during treatment with direct-acting antivirals. ALT, alanine aminotransferase;
EOT, end of treatment; OMB-PAR/rt/DASRBV, ombitasvir-paritaprevir-ritonavir-dasabuvir plus ribavirin; MFI, mean fluorescence intensity; PBL, peripheral blood
lymphocyte; SOF-LED, sofosbuvir plus ledipasvir.
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CD8 cells was upregulated after 6 days of treatment with IL-7 (20 ng · ml1) in vitro
(Fig. 10A and B). Since Bim is upregulated on activated HCV-specific CD8 T cells during
chronic infection (9) and is known to be linked to both TGF-1 secretion (23, 33) and
TRAF1 downregulation (34, 35), we also addressed whether TGF-1 could downmodu-
late TRAF1 expression in pentamer/CD8 cells. In 7 out of 7 pentamer/CD8 cell
assays, TRAF1 expression was downregulated after 48 h of treatment with TGF-1
(5 ng · ml1) in vitro (Fig. 10A and B).
Interestingly, the culture supernatant of PBL from patients with PI, which achieved
a positive expansion after NS3-specific challenge in vitro, showed a higher relative
decrease in TGF-1 levels at day 9 that at day 2 of culture than PBL without expansion
(Fig. 10C, top). In addition, the absolute negative difference in the supernatant TGF-1
concentration was higher in samples with positive expansion than in samples without
proliferation (Fig. 10C, bottom).
Considering the ability of TGF-1 to downregulate TRAF1 expression in vitro and the
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FIG 8 Correlation between TRAF1 expression, exhaustion phenotype, and reactivity of HCV pentamer/CD8 cells. Tests for TRAF1 and Mcl-1 were performed
after 3 h of specific peptide stimulation, while PD-1 and CD127 were assessed directly ex vivo. (A) Correlation between TRAF1 level and CD127, PD-1, and Mcl-1
expression on pentamer/CD8 cells pooled from patients with persistent and resolved infections. (B) PD-1, CD127, and Mcl-1 expression on HCV
pentamer/CD8 cells from HCV patients, according to the TRAF1 level. (C) Rates of HCV pentamer/CD8 cell proliferation after 10 days of specific in vitro
challenge, depending on the level of TRAF1 expression. (D) Representative dot plots showing the PD-1, CD127, and Mcl-1 phenotype (as the MFI) and the
expansion ability (as the percentage of pentamer-binding CD8 cells out of the number of total CD8 cells) according to the TRAF1 level in pentamer/CD8
cells. (E) Histograms of PD-1, CD127, and Mcl-1 expression on pooled pentamer/CD8 cells in relation to the TRAF1 level. *, Spearman correlation test; ¥,
Mann-Whitney U test; negative control, T cell labeling with the nonspecific isotype antibody; Œ, outlier values; LOD, limit of detection; MFI, mean fluorescence
intensity.
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serum TGF-1 concentration in patients with RI and those with PI. Serum samples from
patients with PI showed a slightly higher TGF-1 level than those from patients with RI
(Fig. 10D, left). This difference translated into a negative correlation between the serum
TGF-1 concentration and TRAF1 induction in HCV pentamer/CD8 cells (Fig. 10D,
right). Furthermore, we found that TRAF1dim HCV pentamer/CD8 cells were associ-
ated with lower serum TGF-1 levels than TRAF1low cells (Fig. 10E).
Our data suggest that IL-7 treatment could be a potential strategy to upregulate
TRAF1 by counteracting the TGF-1-mediated downregulation of TRAF1 in exhausted
T cells, in which triggering of TCR alone would not be enough to increase the TRAF1
level.
IL-7 plus 4-1BBL improves HCV pentamer-binding CD8 cell reactivity. Since a
lack of TRAF1 induction in pentamer/CD8 cells correlated with impaired reactivity
and an exhausted phenotype and because we realized that IL-7 treatment in vitro
induced TRAF1 upregulation, we analyzed whether IL-7 plus 4-1BBL treatment could
improve T cell reactivity in patients with PI. We first performed a pilot study in which
we recruited 17 consecutive patients with PI with and without cells detectable ex vivo
















































































































































FIG 9 CD107a-mobilizing and gamma interferon (IFN-)-secreting HCV pentamer/CD8 cells according to the level of TRAF1
expression. Box plots (A) and representative dot plots (B) show the percentage of IFN--secreting and CD107a-mobilizing
pentamer/CD8 cells ex vivo and after 10 days of specific in vitro challenge, according to the TRAF1 level, among cells with
a preserved expansion ability. Œ, outlier value; *, extreme value. The data in each dot plot represent the percentage of positive
cells out of the number of either total CD8 cells or pentamer/CD8 cells. NS, nonsignificant; #, Wilcoxon test; *,
Mann-Whitney U test.
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T cell expansion ability. PBL from these cases were challenged in vitro with the NS31406
peptide and then received one of the following different treatments: 4-1BBL, IL-7, IL-7
plus 4-1BBL, or -galactosidase as a negative control. The number of samples with
positive expansion increased from 35% in the control group to 65% after IL-7 plus
4-1BBL treatment in vitro, while treatment with IL-7 or 4-1BBL alone did not have any
significant effect (Fig. 11A).
Subsequently, considering the negative correlation between the duration of HCV
infection and the ex vivo detection/reactivity of peripheral pentamer/CD8 cells, we
explored whether IL-7 plus 4-1BBL treatment worked with a similar effectiveness in
cases with and without peripheral pentamer/CD8 cells detectable ex vivo. We
analyzed the results of 13 and 39 consecutive proliferation experiments with and
without ex vivo-detectable pentamer/CD8 cells against NS31406 or NS31073 epitopes,
respectively. The cases with detectable cells ex vivo had an infection length of 31 years,
while patients without visible cells had a longer infection span of 40 years (Fig. 11B).
Interestingly, in experiments with peripheral cells detectable ex vivo, 4-1BBL plus IL-7
treatment increased the proportion of T cell-reactive cases from 61% positive expan-
sion in the control group to 92% positive expansion after the addition of 4-1BBL plus
IL-7 treatment (Fig. 11B and E; Table 2). The only nonrestored case was a cirrhotic
(degree of liver fibrosis, F4) rapid fibroser patient (patient 1165P) whose T cell reactivity
was reestablished by treatment with the combination of 4-1BBL, IL-7, and anti-PD-L1
(Fig. 11E). In cases without detectable cells ex vivo, the combination of 4-1BBL plus IL-7
was less effective, only enhancing T cell reactivity in some patients from 20% to 33%
(Fig. 11B and E; Table 2).
Treatment with IL-7, 4-1BBL, and anti-PD-L1 improves HCV pentamer-binding
CD8 cell reactivity in slow fibrosers with long-lasting disease. Because of the
unsatisfactory restoration of T cell reactivity by using treatment with IL-7 plus 4-1BBL
in cases with no pentamer cells detectable ex vivo and long-lasting disease, we
assumed that the exhausted effector memory cell pool could have already disappeared
and a potential PD-1-expressing population with stem cell properties but with an
impaired regenerative capacity could survive in these cases, as recently suggested
(14–16). Therefore, PBL from 20 patients with no pentamer cells detectable ex vivo
were challenged in vitro with the combination of IL-7, 4-1BBL, and anti-PD-L1.
-Galactosidase, anti-PD-L1, and IL-7 plus 4-1BBL were used as controls. PBL from 20%
of cases expanded after either -galactosidase or anti-PD-L1 treatment in vitro, PBL
from 30% of cases proliferated after treatment with the IL-7 plus 4-1BBL combination,
and cells from 50% of the cases expanded with treatment with IL-7, 4-1BBL, and
anti-PD-L1 (Fig. 11C and E). Globally, the cases with no peripheral pentamer/CD8
TABLE 3 Clinical features of recruited patients with CD8/pentamer cells directly
detectable ex vivo according to TRAF1 expressiona
Characteristic






% of patients with PI/RI 64/36 15/85 0.003b
Median (IQR) age (yr) 53 (11) 57 (10) NSc
% of male patients 68 58 NSb
Median (IQR) duration of infection (yr) 34 (11) 32 (5) NSc
Median (IQR) viral load (IU · ml1, log scale) 5.9 (6.6) UDL 0.003c
Mean (SD) ALT concn (IU · ml1) 64 (76) 35 (9) 0.136c
% of patients with significant fibrosis (F3-F4) 57 42 NSb
Median (IQR) liver fibrosis progression rate (Metavir
score [unit · year1])
0.074 (0.07) 0.069 (0.06) NSc
% of patients who were slow fibrosers 45 36 NSb
aALT, alanine aminotransferase; IQR, interquartile range; NS, nonsignificant; PI, persistent infection; RI,
resolved infection after treatment; UDL, under the detection limit.
bDetermined by the chi-square test.
cDetermined by the Mann-Whitney U test.
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cells detectable ex vivo that benefited from the combination of IL-7, 4-1BBL, and
anti-PD-L1 were patients with low rates of liver fibrosis progression (Fig. 11D and E).
Only two cases without cells detectable ex vivo and a liver fibrosis progression rate of
0.07 unit · year1 responded to treatment with the combination of IL-7, 4-1BBL, and
anti-PD-L1, but these two cases had short/midduration infections of 29 years (Fig. 11D
and E).
Hence, our data suggest that IL-7 plus 4-1BBL treatment could improve HCV-specific
cytotoxic T cell reactivity in patients with short/midduration infections. However, in
cases with disease for longer durations, a more severe T cell exhaustion is usually
present, making an additional blockade of the PD-1/PD-L1 checkpoint necessary to
enhance the T cell proliferative potential.
DISCUSSION
In order to establish a persistent infection, HCV induces the exhaustion or even
deletion of the HCV-specific CD8 T cell response (8, 10). Among other strategies, HCV
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FIG 10 TRAF1 regulation by IL-7 and TGF-1 in pentamer/CD8 cells. (A) Levels of TRAF1 expression in pentamer/CD8 cells after -galactosidase (-Gal),
IL-7, and TGF-1 treatments in vitro. Box plots summarize the distribution of the level of TRAF1 expression in each category. (B) Representative dot plots and
histograms showing TRAF1 levels in pentamer/CD8 cells after IL-7, TGF-1, and -galactosidase treatments in vitro. (C) In selected patients with PI, the
dynamics of the TGF-1 levels in PBL culture supernatants between day 2 and day 9 of NS3-specific in vitro challenge, according to cell expansion status. (Top)
Global variation in TGF-1 levels; (bottom) individual variation in TGF-1 levels. Box plots summarize the distribution of either the absolute value or the relative
variation in the TGF-1 level in each category. (D) (Left) Serum TGF-1 level in patients with persistent infection and resolved infection after treatment. Box
plots represent the distribution of the TGF-1 levels in each group. (Right) Correlation between the serum TGF-1 level and TRAF1 expression in HCV
pentamer/CD8 cells after 3 h of specific stimulation. (E) Serum TGF-1 concentration according to the TRAF1 phenotype of HCV pentamer/CD8 cells after
3 h specific stimulation. Box plots summarize the distribution of the TGF-1 level in every group. ¤, Wilcoxon test; #, Mann-Whitney U test; ¥, Spearman
correlation test; Œ, outlier value; MFI, mean fluorescence intensity.
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modulates T cell costimulatory pathways for this purpose (36). An understanding of
these pathways could lead to the development of new therapies focused on the
restoration of these impaired checkpoints (37). 4-1BB/4-1BBL is a costimulatory check-
point that has been involved both in effector capabilities and in inhibition of the
Bim-regulated apoptosis of virus-specific cytotoxic T cells during influenza virus and
human immunodeficiency virus (HIV) infections (34, 35). However, this pathway can
become dysfunctional due to the virus-induced loss of its key signal transducer (TRAF1)
(23). Although the triggering of 4-1BB/4-1BBL could be a promising target for improv-
ing T cell reactivity during HCV infection, this strategy has not been effective in
restoring intrahepatic HCV-specific CD8 T cells (13), further adding to the potential
role of TRAF1 downregulation (23).
In view of this, we designed a cross-sectional study to understand the role of the
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FIG 11 Restoration of pentamer/CD8 cell reactivity. (A) In patients with persistent infection, the percentage of assays with pentamer/CD8 cell expansion
after 10 days of NS31406 challenge in vitro in the presence of treatment with -galactosidase (-gal), IL-7, 4-1BBL, or IL-7 plus 4-1BBL. (B) Cases with
pentamer/CD8 cell proliferation after antigen-specific stimulation in the presence of treatment with -galactosidase or IL-7 plus 4-1BBL, according to the
detection of peripheral pentamer/CD8 cells ex vivo. The rate of liver fibrosis progression and the duration of infection are expressed as the median plus
interquartile range. Liver fibrosis is described by the Metavir score. (C) Percentage of cases without cells detectable ex vivo with pentamer/CD8 cell
proliferation after treatment with -galactosidase, anti-PD-L1, IL-7 plus 4-1BBL, or IL-7, 4-1BBL, and anti-PD-L1. (D) In patients with PI without cells detectable
ex vivo, the liver fibrosis progression rate according to the proliferative potential after specific in vitro treatment with IL-7, 4-1BBL, and anti-PDL1. Box plots
summarize the distribution of the liver fibrosis progression rate in each group. In the group positive for expansion, one case was not included because the
estimated date of infection was unknown. (E) Representative dot plots showing the expansion of CD8/pentamer cells in the presence of different treatment
combinations, according to the detection of CD8/pentamer cells ex vivo and the liver fibrosis progression rate. The data in each dot plot show the frequency
of pentamer/CD8 cells out of the number of total CD8 cells. EV, escape variant; F, Metavir fibrosis score; N.D., not done; Œ, outlier; W.T.; wild type; #,
Friedman test; , chi-square test; ¤, Wilcoxon test; &, Mann-Whitney U test.
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enhance HCV-specific CD8 T cell reactivity. We compared the specific T cell response
between patients with RI after treatment and patients with PI. We selected responders
to anti-HCV treatment as the positive controls, since reactive HCV-specific CD8 T cell
detection after treatment correlates with a sustained viral response in IFN-based and
-free treatments (2, 3, 17), probably by T cell control of temporary occult traces of HCV
(4–7). In addition, CMV-specific CD8 T cell responses were also assessed in patients
with PI as an internal positive control due to the ability of these cells to naturally
restrain a persistent viral infection. We chose two HLA-A2 immunodominant NS3
epitopes (NS31406 and NS31073) with a low frequency of escape variants as the model
for our study (38, 39). We performed epitope sequencing in a few patients with PI to
address the rate of escape variants in our cohort. One hundred percent of the samples
with NS31073 and 70% of the samples with NS31406 tested were wild type or had
conservative amino acid substitutions (32, 40). Therefore, the results obtained with our
cohort allowed us to draw conclusions about the influence of HCV pressure on TRAF1
expression.
First, we assessed the basic functional and phenotypic features of HCV-specific
CD8 cells in the recruited cases. We observed that the chance of detecting ex vivo
peripheral pentamer/CD8 cells was similar between patients with RI and patients
with PI, although this was probably due to different causes; the lack of sustained
priming in patients with RI and the overwhelming persistent antigen stimulation during
PI could impact the peripheral detection of HCV-specific CD8 T cells, as suggested by
mathematical models (41). The only factor predictive of T cell detection was the
duration of infection in combination with the speed of liver fibrosis development. We
calculated the rate of liver fibrosis progression based on the estimated date of infection
and the result of one liver biopsy or liver transient elastography at the time of
recruitment into the study or the date of cirrhosis diagnosis, based on clinical records.
This approach has been shown to be valid, since Poynard et al. found that the
estimated rate of liver fibrosis progression per year, based on one liver biopsy sample
from patients for whom the duration of infection was known, was similar to the rates
of progression estimated from paired biopsy samples (42).
In our study, the longer that the duration infection was and the higher that the rate
of liver fibrosis progression was, the lower was the likelihood that HCV-specific CD8
effector cells would be detected. This finding could mean that in long-lasting infection,
the HCV-specific CD8 effector cells could both be more prone to apoptosis and not be
replenished due to a severely impaired progenitor pool (15, 16). The misbalance
between proapoptotic proteins (8) and antiapoptotic proteins (9, 17) could lead to the
progressive deletion of the effector memory cell pool over the years, like that which
occurs with LCMV-specific CD8 cells during chronic infection (31). Finally, after the loss
of these effector cells, the progression of liver fibrosis could advance faster.
To better define the baseline features of the studied cells, we carried out a more
sensitive analysis of the memory cell subpopulations in our cohort (43, 44). A homo-
geneous effector memory phenotype was observed in patients with RI, while patients
with PI had minor populations of TEMRA and naive-like T cells but also a major group
of CD28 PD-1-expressing effector memory cells that could theoretically be sensitive to
a PD-1 blockade (29). We could also speculate that PD-1 could affect not only the
positive checkpoint CD28 (45) but also other positive costimulatory pathways, such as
the 4-1BB/TRAF1 pathway, in a similar manner. In fact, we observed in our study a
negative correlation between PD-1 expression and TRAF1 expression.
In patients with PI, the reactivity of CD8 T cells was clearly reduced for HCV-specific
CD8 cells but not for paired CMV-specific CD8 cells, as predicted by mathematical
models (41). In line with the reduced peripheral T cell detection, this HCV-specific
hyporeactivity was stronger in long-lasting disease. This could be due to different levels
of exhaustion of the targeted T cells according to the duration of HCV infection. The
population keeping a proliferative potential during a chronic viral infection seems to be
either a stem cell-like subset with a PD-1dim T-bethigh phenotype (16) or a memory-like
pool characterized by the phenotype TCF1 PD-1 CD127 T-betdim eomesoderminlow
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(Eomeslow) (15, 17). They are mainly found in the lymphoid tissues (15) but can be also
detected in the peripheral compartment during chronic HCV infection and after
treatment-induced resolved HCV infection (16, 17). Although these populations could
be contracted during PI, it is possible that they could still be targeted by immunother-
apeutic approaches, such as PD-L1 blockade or IL-7 stimulation, since they expressed
the respective receptors. Nevertheless, the immunomodulation needs of these cells
could be different depending on the infection stage.
After we described the basic features of the peripheral HCV-specific CD8 T cells
according to viral control and the duration of infection, we analyzed whether the
4-1BB/TRAF1 pathway could be involved in the observed progressive impairment of T
cell reactivity in the course of the natural history of the PI. The level of antigen-specific
TRAF1 expression induced in HCV-specific CD8 T cells was higher in patients with RI
than in patients with PI. In all the experiments with positive expansion, the TRAF1
phenotype was TRAF1high after proliferation, suggesting that TRAF1 could play a role in
T cell reactivity. We also detected a slightly higher TRAF1 level in bulk CD8 cells from
patients with RI and PI after specific stimulation with HCV and CMV peptides, respec-
tively, than in patients with PI stimulated with HCV antigens. This finding could be
explained by the occurrence of bystander CD8 cell activation in cultures with specific
T cells reactive to the cognate antigen (30). Besides the cross-sectional difference in
TRAF1 induction between patients with RI and patients with PI, the role of HCV pressure
on TRAF1 inducibility in HCV-specific CD8 T cells was also confirmed by the higher
level of TRAF1 expression in patients with PI harboring HCV escape variants (32) and by
the upregulation of TRAF1 after anti-HCV treatment in patients with PI reaching a
sustained viral response.
In addition to determining a low level of TRAF1 in HCV-specific CD8 T cells during
chronic HCV infection, we also found that the TRAF1low phenotype correlated with
impaired reactivity and an exhausted phenotype. TRAF1low cells had a lower prolifer-
ative potential and lower levels of CD107a mobilization after the antigen-specific
triggering of TCR than TRAF1dim cells, as well as an exhausted and proapoptotic
phenotype (CD127low, PD-1high, Mcl-1low). It is possible that the low Mcl-1 level in
TRAF1low cells could not counteract the Bim upregulation that occurs after an antigen
encounter during chronic HCV infection (9). The loss of TRAF1 has been described to
lead to Bim upregulation in a murine model of influenza virus infection (35). Conse-
quently, the TRAF1low phenotype could be associated with a Bim/Mcl-1 misbalance that
induces T cell apoptosis. The triggering of 4-1BB has been shown to restore this
balance, reestablishing T cell reactivity through Bim downregulation (34). To make this
pathway operative in patients with chronic HCV infection, it would be necessary to
restore its fundamental signal transducer (TRAF1). To achieve this goal, we tested the
effects of two regulatory cytokines with modulatory properties on TRAF1 in LCMV
infection (23). We demonstrated that IL-7 significantly increased the level of TRAF1
expression in HCV-specific CD8 cells, while TGF-1 had the opposite effect. Moreover,
in vitro cultures of cells from patients with PI with positive HCV-specific CD8 cell
proliferation showed a consistent decrease in the TGF-1 level that was lower in most
cases of nonexpanding cells. This difference could be explained by the IFN- secretion
by reactive HCV-specific CD8 cells observed after proliferation in our cohort, since
IFN- is able to inhibit the differentiation of T cells into inducible TGF-1-secreting T
regulatory cells (iTreg) (46). All these data suggested that TGF-1 could affect T cell
activation through TRAF1 downregulation. This situation might also occur in vivo, and
in fact, we found a slightly higher TGF-1 level in serum from patients with PI than in
serum from patients with RI. This translated into a negative correlation between the
TGF-1 concentration and the induction of TRAF1 expression after specific stimulation
in peripheral HCV-specific CD8 cells. Previous studies have also shown that HCV-
specific CD8 cells from patients with chronic HCV infection are able to secrete TGF-1
after the specific triggering of TCR (24), that HCV itself is able to induce TGF-1
expression by liver cells (25, 26), and that the levels of TGF-1-secreting Treg could be
increased during PI (47), all of which could contribute to TRAF1 downregulation.
Moreno-Cubero et al. Journal of Virology
January 2018 Volume 92 Issue 2 e01443-17 jvi.asm.org 18







However, the effect of TGF-1 ex vivo is likely most relevant in exhausted T cells, in
which the lack of TRAF1 upregulation after the triggering of TCR (22) could not
overcome the TGF-1-induced loss of TRAF1. In fact, in reactive CMV-specific CD8 T
cells from cases with PI, the TRAF1 levels after specific in vitro challenge were similar to
those in HCV-specific cells from patients with RI, despite the different serum TGF-1
level.
Once we observed that treatment with IL-7 in vitro could upregulate TRAF1 expres-
sion, we hypothesized that stimulation with IL-7 plus 4-1BB could enhance HCV-specific
CD8 T cell reactivity. Although during chronic hepatitis C the IL-7 receptor is down-
regulated in intrahepatic HCV-specific CD8 T cells (8), a peripheral pool of CD127dim
cells can still be detected (8, 17), and consequently, this subset could respond to our
therapy. Our data showed a significant global improvement in the number of reactive
patients with PI after treatment with IL-7 plus 4-1BBL but not after treatment with either
IL-7 or 4-1BBL alone. Therefore, the reported failure of 4-1BBL to improve the intrahe-
patic HCV-specific cytotoxic response (13) could be due to the lack of the key signal
transducer of this checkpoint (TRAF1). Nevertheless, the treatment with IL-7 plus 4-1BBL
was completely active only in patients with short/midduration infections, characterized
by HCV-specific CD8 cells detectable ex vivo, while in cases without visible cells and
long-lasting disease, the treatment was less effective.
Based on the previous reports of peripheral stem cell-like subsets (16) and
progenitor memory-like subsets (17) expressing PD-1 during chronic viral infections,
we tested whether PD-1 blockade, in addition to 4-1BB stimulation after IL-7-
mediated TRAF1 upregulation, could restore T cell reactivity in these more ad-
vanced cases. IL-7 treatment alone during the initial effector phase can prevent T
cell exhaustion (27), but later, exhausted T cells respond poorly to IL-7 (48).
Interestingly, anti-PD-L1 could improve IL-7 receptor signaling and could again
make exhausted virus-specific CD8 cells sensitive to the effect of IL-7 (49). We
found that treatment with anti-PD-L1, IL-7, and 4-1BBL in vitro restored the reac-
tivity of HCV-specific CD8 cells in a significant proportion of those cases without
pentamer/CD8 cells detectable ex vivo.
To better define this response, we looked for predictive factors associated with the
recovery of T cell reactivity in these cases. The responder patients were those with a low
rate of liver fibrosis progression. Supporting our finding, it has been reported that
TGF-1 blockade restores the HCV-specific cytotoxic T cell effector response in slow
fibrosers but not in rapid fibrosers (50). According to our data, this improvement could
be linked to TRAF1 upregulation as a consequence of either TGF-1 blockade, as in the
previously described study (50), or IL-7 stimulation, as in our work.
In difficult-to-treat HCV cases with advanced disease, the potential lack of restora-
tion of a specific T cell response after treatment could also be one of the causes of
failure of treatment with DAA, due to the inability to control minor viral traces resistant
to treatment, favoring subsequent viral relapse (3–5, 51). In these cases, additional
immunomodulatory treatments, like the one proposed in this paper, could be an
interesting add-on strategy to increase the efficacy of DAA.
To sum up, our data support novel ways of restoring T cell responses in patients
with chronic HCV infection, stressing the key role of TRAF1 signaling, which could
be a promising target for immunotherapy in patients with chronic viral infections
and tumors. IL-7-induced TRAF1 upregulation could be a useful strategy in cases with
still detectable exhausted peripheral effector memory cells. Nevertheless, in our cohort,
patients without detectable HCV-specific cells maintained a target population that
could be expanded by additional blockade of the negative checkpoint, PD-1/PD-L1.
MATERIAL AND METHODS
Patients. Seventy-seven human leukocyte antigen (HLA)-A2-positive HCV genotype 1-positive pa-
tients with PI (n  35) and resolved infection (RI) after treatment (n  42) were recruited at the
Guadalajara University Hospital, Guadalajara, Spain. Patients with human immunodeficiency virus (HIV)
coinfection, any other concurrent liver disease, risk factors for liver steatosis, or levels of alcohol
consumption greater than 40 g per day were excluded. Heparinized peripheral blood (60 ml) and a serum
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sample were withdrawn at recruitment. The samples from cases with RI were taken at least 12 weeks after
the end of treatment. In two patients with PI subjected to DAA treatment, peripheral blood samples were
also withdrawn before, at the end of, and 12 weeks after treatment. The duration of infection was
estimated according to the moment of exposure to the HCV risk factor (52). The time point for the
diagnosis of liver cirrhosis was defined by either clinical/analytical data or the estimation of fibrosis
through liver stiffness or biopsy, obtained from the patients’ clinical records. A liver transient elastog-
raphy with a FibroScan-402 device (Echosens, France) or a liver biopsy was carried out at the time of
enrollment. The speed of liver fibrosis progression was calculated by the ratio between liver fibrosis score
and either the estimated duration of infection or the time gap until the diagnosis of cirrhosis. Fibrosis was
categorized according to the Metavir score (53). An individual with a fibrosis progression rate of 0.06
units · year1 was considered a slow fibroser, while one with a rate higher than 0.06 units · year1 was
categorized as a mid/rapid fibroser (42). The Research Ethical Committee of the Guadalajara University
Hospital (Guadalajara, Spain) approved the study protocol, which conformed to the ethical guidelines of
the 1975 Declaration of Helsinki. All the patients enrolled in the study gave written informed consent.
Table 1 summarizes the clinical features of the study groups.
Synthetic peptides and pentamers. HLA-A2-restricted peptides corresponding to the HCV geno-
type 1 NS3 region from positions 1406 to 1415 (NS31406 –1415; KLVALGINAV), NS31073–1081 (CINGVCWTV),
cytomegalovirus (CMV) pp65495–504 (NLVPMVATV), and phycoerythrin (PE)-conjugated HLA-A2/peptide
pentameric complexes (pentamer) loaded with the same NS3 and CMV peptides were purchased from
ProImmune (Oxford, UK). These HCV pentamers allow the detection of CD8 cells specific for the
epitopes NS31073 of HCV genotypes 1a (CINGVCWTV) and 1b (CVNGVCWTV) and NS31406 of genotype 1a
(KLVALGINAV and KLVALGVNAV) (40).
Virological assessment and tissue typing. Screening for the HLA-A2 haplotype, anti-HCV, HCV
genotype, HCV RNA load, and HCV-NS31406 –1415 and NS31073–1081 epitope sequences was performed as
previously reported (8). The consensus sequences and sequences with conservative amino acid changes
within the consensus sequence were considered the wild-type sequence. A test for CMV IgG status was
carried out for patients with PI by use of the Architect CMV IgG assay (Abbott Laboratories, Ireland).
Antibodies. The following mouse anti-human monoclonal antibodies (MAb) were used for flow
cytometry: anti-CD8-peridinin chlorophyll (PerCP) (clone SK1; BioLegend, San Diego, CA), anti-CD8-
allophycocyanin (APC)-H7 (clone SK1; Becton Dickinson Bioscience, San Jose, CA), anti-CD127-fluorescein
isothiocyanate (FITC) (clone eBioRDR5; eBioscience Inc., San Diego, CA), anti-PD-1–FITC (clone MIH4;
eBioscience Inc., San Diego, CA), anti-CD3-V500 (clone SK7; Becton Dickinson Bioscience, San Jose, CA),
anti-CD4-PerCP (clone SK3; Becton Dickinson Bioscience, San Jose, CA), anti-CD19-PerCP-cyanine 5.5
(Cy5.5) (clone SJ25C1; Becton Dickinson Bioscience, San Jose, CA), anti-CD45RA-APC (clone MEM-56;
Exbio, Prague, Czech Republic), anti-C-C chemokine receptor type 7 (CCR7)-PE-Cy7 (clone G043H7;
BioLegend, San Diego, CA), anti-CD28-Pacific blue (PB) (clone CD28.2; Exbio, Prague, Czech Republic),
anti-gamma interferon (anti-IFN-)-FITC (clone 25723; R&D Systems, Minneapolis, MN), and anti-CD107a-
Alexa Fluor 488 (AF488) (clone H4A3; BioLegend, San Diego, CA). The following unlabeled MAb were also
used: TRAF1 rabbit anti-human immunoglobulin (clone 45D3; Cell Signaling, Boston, MA) and myeloid
cell leukemia 1 protein (Mcl-1) rabbit anti-human immunoglobulin (clone Y37; Epitomics, Burlingame,
CA). Goat anti-rabbit IgG-AF647 (Invitrogen, Carlsbad, CA) was used to develop primary unlabeled MAb.
The following isotype controls were purchased: mouse IgG1-FITC (clone MOPC-21; BioLegend, San Diego,
CA), mouse IgG1-Alexa Fluor 488 (AF488) (clone MOPC-21; BioLegend, San Diego, CA), and mouse
IgG2b-FITC (clone 133303; R&D Systems, Minneapolis, MN).
Surface and intracellular phenotypic analysis. Peripheral HCV-specific CD8 cells were identified
and quantified using pentamer staining as previously described (8). In patients with pentamer/CD8
cells detectable ex vivo, surface and intracellular staining for CD127, PD-1, Mcl-1, and TRAF1 was
performed. Surface CD127 and PD-1 staining was carried out as previously reported (8). For Mcl-1 and
TRAF1 studies, peripheral blood lymphocytes (PBL) were previously stimulated for 3 h with 2 M specific
peptide to induce antigen-specific protein expression. Harvested cells were first stained with pentamers,
and then a combined staining for CD8 and intracellular molecules was performed using Cytofix/
Cytoperm (Becton Dickinson Bioscience, San Jose, CA). Indirect labeling with rabbit anti-human MAb was
used to detect Mcl-1 and TRAF1, followed by the further addition of AF647-conjugated goat anti-rabbit
IgG. TRAF1 was also tested after 6 days of treatment with IL-7 (20 ng · ml1; eBioscience Inc., San Diego,
CA) and after 48 h of treatment with TGF-1 (5 ng · ml1; Invitrogen, Carlsbad, CA) in vitro, with
-galactosidase (2 g · ml1; Santa Cruz Biotechnology, Santa Cruz, CA) being used as a negative control.
TRAF1 was also longitudinally tested in two patients with PI subjected to anti-HCV treatment with DAA.
For each sample, an aliquot stained with surface antigens and the intracellular secondary antibody was
used as a negative control. In the rest of the stainings, appropriate isotype controls were used. For the
degranulation assay and IFN- staining, PBL were challenged in vitro as previously described (9).
Anti-CD107a-AF488 was added at the beginning of the stimulation. At the time of harvest, cells were
stained with pentamer-PE and anti-CD8-PerCP, washed, and fixed and permeabilized using Cytofix/
Cytoperm for subsequent intracellular staining with anti-IFN-–FITC. Stained cells were analyzed on a
FACSCalibur flow cytometer using CellQuest software (Becton Dickinson Bioscience, San Jose, CA). In
selected cases, an extended MAb panel (CD3-V500, CD28-PB, pentamer-PE, CD19-PerCP-Cy5 plus CD4-
PerCP, CCR7-PE-Cy7, CD45RA-APC, CD8-APC-H7) was used to obtain a detailed description of the
memory phenotype using a more sensitive detection method (43). These samples were acquired on a
FACSCanto II flow cytometer (Becton Dickinson Bioscience, San Jose, CA) and analyzed using Infinicyt
software (Cytognos, Spain). Phenotype comparisons were carried out using the mean fluorescence
intensity (MFI) or the percentage of positive cells.
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Specific T cell proliferation. For the in vitro stimulation experiments, 4-1BBL (Enzo Life Sciences,
Farmingdale, NY), anti-programmed cell death protein ligand 1 (PD-L1) MAb (eBioscience Inc., San Diego,
CA), IL-7 and IL-2 (R&D Systems, Minneapolis, MN), and -galactosidase were purchased. PBL-specific
in vitro challenge with the NS31406 –1415, NS31073–1081, or CMV pp65495–504 peptide was carried out as
previously described (8). After specific in vitro expansion, TRAF1 expression by pentamer/CD8 cells
from a number of patients was analyzed. PBL from selected patients with PI were also cultured with
specific peptides in the presence of the following treatments: IL-7 (20 ng · ml1), 4-1BBL (1 g · ml1),
anti-PD-L1 blocking MAb (2 g · ml1), -galactosidase (2 g · ml1), or the combinations IL-7 plus
4-1BBL and IL-7, 4-1BBL, and anti-PD-L1. Expansion was considered positive when the pentamer/CD8
cells were found in a cluster shape and the frequency of positive cells was at least 4 times higher than
the ex vivo percentage with a minimum of 20 detectable dots.
TGF-1 ELISA. The levels of active soluble TGF-1 in serum from patients with RI and PI were
measured using a commercial enzyme-linked immunosorbent assay (ELISA) kit (Quantikine ELISA human
TGF-1; R&D Systems, Minneapolis, MN), according to the manufacturer’s instructions. The lower level of
detection was 4.61 pg · ml1. In cases in which pentamer/CD8 cells were detectable ex vivo, the
TGF-1 level was correlated with TRAF1 expression. In patients with PI, the TGF-1 level in the
supernatant of PBL cultures was also tested at days 2 and 9 of the 10-day specific in vitro challenge to
check TGF-1 kinetics according to the expansion status.
Statistical analysis. Every epitope tested in each patient was considered an independent case.
Quantitative and categorical variables are summarized as medians plus interquartile ranges (IQR) and as
frequency distributions, respectively. Pearson’s chi-square test, the Mann-Whitney U test, the Wilcoxon
test, the Friedman test, the Spearman correlation test, and the linear trend test were employed where
appropriate. All tests were two-tailed, and a P value of 0.05 was considered significant.
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